TIME FOR REIMBURSEMENT FOR ORPHAN DRUGS IN EU5

被引：0
|
作者：
Prada, M. [1 ]
Berard, I [2 ]
Walzer, S. [3 ]
Darba, J. [4 ]
Greenwood, B. [5 ]
机构：
[1] Intexo, Rome, Italy
[2] NEXTEP, Paris, France
[3] MArS Market Access & Pricing Strategy GmbH, Weil Am Rhein, Germany
[4] Univ Barcelona, Barcelona, Spain
[5] Decideum, London W8 7JB, England
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.04.1761
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSY119
引用
收藏
页码：S264 / S264
页数：1
相关论文
共 50 条
  • [1] TIME TO REIMBURSEMENT FOR ORPHAN DRUGS IN EU5 IN THE LAST FIVE YEARS
    Molchanova, E.
    Benazet, F.
    Vollmer, L.
    Pomares, E.
    Danev, V
    Prada, M.
    VALUE IN HEALTH, 2020, 23 : S701 - S701
  • [2] TIME FOR REIMBURSEMENT FOR ORPHAN DRUGS IN EU5 IN THE LAST THREE YEARS
    Prada, M.
    Benazet, F.
    Berard, I
    Vollmer, L.
    Cuesta, M.
    Guterres, S.
    VALUE IN HEALTH, 2019, 22 : S854 - S854
  • [3] TIME TO REIMBURSEMENT FOR ONCOLOGY DRUGS IN EU5
    Prada, M.
    Berard, I
    Walzer, S.
    Darba, J.
    Greenwood, B.
    VALUE IN HEALTH, 2018, 21 : S47 - S47
  • [4] ORPHAN DRUG ACCESS AND REIMBURSEMENT IN THE EU5: CYSTIC FIBROSIS AND DUCHENNE MUSCULAR DYSTROPHY
    Privolnev, Y.
    Cox, J.
    Breen, M.
    Reyes, A.
    VALUE IN HEALTH, 2018, 21 : S459 - S459
  • [5] DIFFERENCE BETWEEN UNITED STATES AND EU AUTHORISATION TIMELINES AND TIME TO REIMBURSEMENT IN THE EU5
    Sun, D.
    Beckerman, R.
    VALUE IN HEALTH, 2014, 17 (03) : A17 - A17
  • [6] TIME TO MARKET AND PRICE COMPARISON FOR BIOSIMILAR DRUGS IN EU5
    Lopez, N.
    Prada, M.
    Berard, I
    Schleich, W.
    Melson, C.
    VALUE IN HEALTH, 2018, 21 : S186 - S187
  • [7] SOLUTIONS TO THE COMPARATOR QUESTION IN THE ABSENCE OF LICENSED COMPARATORS? A RETROSPECTIVE ANALYSIS OF ORPHAN DRUG AND GENE THERAPY REIMBURSEMENT IN EU5 MARKETS
    Mumford, A.
    English, B.
    Sopena, L.
    Munetsi, R.
    VALUE IN HEALTH, 2020, 23 : S671 - S672
  • [8] THE CHANGING LANDSCAPE OF ORPHAN DRUG PROVISION IN THE EU5 AND THE UNITED STATES
    McConkey, D.
    VALUE IN HEALTH, 2011, 14 (03) : A18 - A19
  • [9] MARKET ACCESS, PRICING AND REIMBURSEMENT PROCESSES FOR ORPHAN DRUGS IN THE EU-5 COUNTRIES: A COMPARATIVE ASSESSMENT
    Vollmer, L.
    Prada, M.
    Benazet, F.
    Berard, I
    Lopez, N.
    Guterres, S.
    Walzer, S.
    VALUE IN HEALTH, 2019, 22 : S854 - S854
  • [10] THE PROMISING FUTURE OF DIGITAL HEALTH: A ROAD TO REIMBURSEMENT IN US & EU5 MARKETS?
    Sheppard, H.
    VALUE IN HEALTH, 2023, 26 (12) : S432 - S432
12345